9 Most Undervalued Healthcare Stocks to Buy Now

7. Organon & Co. (NYSE:OGN)

PE Ratio: 12.28

Organon & Co. (NYSE:OGN) is one of the most undervalued healthcare stocks to buy now.

TheFly reported on April 10 that Evercore ISI pointed to media reports suggesting that Sun Pharmaceutical may be nearing a $12 billion offer for OGN, while noting the company described the claims as speculative with no confirmable developments. The firm indicated that regardless of whether a transaction materializes, the situation supports improving valuation sentiment across the specialty pharmaceutical segment, particularly given Organon’s reputation as one of the more challenged players in the group.

Adding to its business developments, Organon & Co. (NYSE:OGN) announced on April 15 that its VTAMA (tapinarof) cream, 1%, received a strong endorsement in the 2026 pediatric atopic dermatitis guidelines issued by the American Academy of Dermatology.

The treatment was recognized as the only non-steroidal topical option supported by high-certainty clinical evidence for use in children aged two years and older across all disease severities. The recommendation was supported by data from late-stage clinical trials, reinforcing the therapy’s safety and effectiveness profile. The updated guidelines provide clinicians with structured, evidence-backed direction for managing pediatric skin conditions, highlighting the importance of tailored treatment approaches for younger patients.

Organon & Co. (NYSE:OGN) is a global healthcare company spun off from Merck in 2021, focused on women’s health, biosimilars, and established medicines. It is based in New Jersey and operates in over 140 countries.